CN102869360B - 治疗高血压的医药组合物及方法 - Google Patents

治疗高血压的医药组合物及方法 Download PDF

Info

Publication number
CN102869360B
CN102869360B CN201180022318.4A CN201180022318A CN102869360B CN 102869360 B CN102869360 B CN 102869360B CN 201180022318 A CN201180022318 A CN 201180022318A CN 102869360 B CN102869360 B CN 102869360B
Authority
CN
China
Prior art keywords
amlodipine
dextromethorphan
hypertension
blood pressure
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180022318.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102869360A (zh
Inventor
陈肇文
王锡杰
庄欣怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsh Biopharm Co ltd
Original Assignee
Tsh Biopharm Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsh Biopharm Co ltd filed Critical Tsh Biopharm Co ltd
Publication of CN102869360A publication Critical patent/CN102869360A/zh
Application granted granted Critical
Publication of CN102869360B publication Critical patent/CN102869360B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180022318.4A 2010-05-03 2011-04-29 治疗高血压的医药组合物及方法 Expired - Fee Related CN102869360B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33054010P 2010-05-03 2010-05-03
US61/330,540 2010-05-03
PCT/CN2011/073560 WO2011137734A1 (en) 2010-05-03 2011-04-29 Pharmaceutical composition and method for treating hypertension

Publications (2)

Publication Number Publication Date
CN102869360A CN102869360A (zh) 2013-01-09
CN102869360B true CN102869360B (zh) 2015-03-25

Family

ID=44903590

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180022318.4A Expired - Fee Related CN102869360B (zh) 2010-05-03 2011-04-29 治疗高血压的医药组合物及方法

Country Status (11)

Country Link
US (2) US20130053411A1 (https=)
EP (1) EP2566478A4 (https=)
JP (1) JP5847162B2 (https=)
KR (1) KR20130061148A (https=)
CN (1) CN102869360B (https=)
AU (1) AU2011250485B2 (https=)
BR (1) BR112012028153A2 (https=)
MY (1) MY161853A (https=)
RU (1) RU2571284C2 (https=)
TW (1) TWI583383B (https=)
WO (1) WO2011137734A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102635B2 (en) * 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2017028814A1 (en) * 2015-08-20 2017-02-23 Tsh Biopharm Corporation Ltd. Pharmaceutical composition comprising amlodipine and dextromethorphan
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
KR20240096848A (ko) 2017-01-25 2024-06-26 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023947A (zh) * 2006-02-24 2007-08-29 江传箕 用于杀菌、抑菌和抗炎的组合物及其方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
JPH06500554A (ja) * 1990-08-23 1994-01-20 ザ・チルドレンズ・メディカル・センター・コーポレイション エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療
JPH04368338A (ja) * 1991-06-12 1992-12-21 Taisho Pharmaceut Co Ltd 鎮咳剤
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5560913A (en) 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
EP1505068A4 (en) * 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2987788A1 (en) * 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid and opioid-like compounds and uses thereof
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR100476636B1 (ko) 2002-09-11 2005-03-17 한림제약(주) 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법
US7863287B2 (en) * 2002-12-18 2011-01-04 Wyeth Llc Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US8569374B2 (en) 2004-09-16 2013-10-29 The Trustees Of The University Of Pennsylvania NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
US8569364B2 (en) * 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023947A (zh) * 2006-02-24 2007-08-29 江传箕 用于杀菌、抑菌和抗炎的组合物及其方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
小胶质细胞与炎症介导的神经系统退行性病变;薛旸等;《生命科学》;20070228;第19卷(第1期);第43-46页 *
氧化应激在D5多巴胺受体基因敲除小鼠血压升高中的作用研究;杨志伟等;《中国比较医学杂志》;20060331;第16卷(第3期);第129-134页 *

Also Published As

Publication number Publication date
KR20130061148A (ko) 2013-06-10
TW201206437A (en) 2012-02-16
US20130053411A1 (en) 2013-02-28
EP2566478A1 (en) 2013-03-13
JP5847162B2 (ja) 2016-01-20
US9744165B2 (en) 2017-08-29
MY161853A (en) 2017-05-15
AU2011250485B2 (en) 2016-07-07
AU2011250485A1 (en) 2012-12-06
EP2566478A4 (en) 2014-04-30
BR112012028153A2 (pt) 2018-08-07
CN102869360A (zh) 2013-01-09
WO2011137734A1 (en) 2011-11-10
TWI583383B (zh) 2017-05-21
RU2012151051A (ru) 2014-06-10
US20160235741A1 (en) 2016-08-18
JP2013525460A (ja) 2013-06-20
RU2571284C2 (ru) 2015-12-20

Similar Documents

Publication Publication Date Title
US9744165B2 (en) Method for treating hypertension
Wang et al. Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca2+-activated K+ channels
HUT77315A (hu) Loratadinszármazék allergiás és egyéb betegségek kezelésében való alkalmazásra
KR20040032141A (ko) 제약 복합제제
CA2124445A1 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
WO2019241020A1 (en) Serdexmethylphenidate conjugates, compositions and methods of use thereof
US20070032471A1 (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
EP1676573A1 (en) Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
CA2357925A1 (en) Prophylactic use of n-methyl-d-asparate (nmda) antagonists
ES2847904T3 (es) Medicamento para la prevención o el tratamiento de la hipertensión
Guarneri et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers
JP2012532855A (ja) 医薬として使用するための組合せ製剤
JPS63310867A (ja) 抗鬱病剤作用を有する新規な結合生成物
US5571827A (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
CN105924382B (zh) S-马尼地平盐酸盐i晶型及其制备方法
JP5559696B2 (ja) 糖尿病性腎症の治療剤
EP0965341A2 (en) Combination of dofetilide and a calcium channel blocker
TW201304775A (zh) 使用依普羅沙坦與氨氯地平治療高血壓的組成物和方法
HK40123243A (zh) 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法
JP2011020957A (ja) アルツハイマー病治療薬
MXPA99004460A (en) Combination of dofetilida and a blocking of the calculates
EP0663822A1 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
WO1994014441A1 (en) Use of an enantiomeric dihydropyridine
JPH10182596A (ja) 脂質代謝改善剤
HK1036758A1 (en) Antihypertensive combination of valsartan and calcium channel blocker

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150325

Termination date: 20200429